Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
Discussion centered around real-world data following the approval of ruxolitinib as a treatment option for patients with chronic GvHD as well as discussing treatment selection for patients with chronic GvHD, with special consideration for treatment sequencing.
EP: 1.The Chronic GvHD Landscape: Risk Factors and Diagnosis
EP: 2.First-line Treatment for Patients with Chronic GvHD
EP: 3.Defining and Managing Steroid Refractory Chronic GvHD
EP: 4.Role of Ruxolitinib in Steroid-Refractory Chronic GvHD
EP: 5.Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil
EP: 6.Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients
Now Viewing
EP: 7.Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD
EP: 8.Future Directions in Chronic GvHD
Related Videos
Related Content
